

Rakuten Medical

Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Illuminox™ technology platform.

About Rakuten Medical, Inc.

Company Name	Rakuten Medical, Inc.		
Chairman and CEO	Hiroshi Mikitani		
Office Locations	Rakuten Medical, Inc.	San Mateo, USA San Diego, USA	Corporate HQ R&D HQ
Subsidiaries	Rakuten Medical Japan K.K.	Tokyo, Japan	Asia Operations
	Rakuten Medical, GmbH	Sinn-Fleisbach, Germany	Device Development
	Rakuten Medical Europe B.V.	Amsterdam, Netherlands	Europe Operations
	Rakuten Medical Taiwan Inc.*	Taipei, Taiwan	Taiwan Operations
	Medlight SA**	Ecublens, Switzerland	Device Development and Manufacturing
Founded	2010 (Aspyrian Therapeutics, Inc.)		
Business	Development, manufacturing and commercialization of drug and medical devices		
Employees	Approx. 240 (Including subsidiaries. As of August 2020)		

* Rakuten Medical Taiwan Inc. is a subsidiary of Rakuten Medical Japan K.K.

** Medlight SA is an indirect wholly owned subsidiary of Rakuten Medical Inc.

Rakuten Medical History

2010	<ul style="list-style-type: none"> • Founding of Aspyrian Therapeutics, Inc. in San Diego, California, U.S.
2011	<ul style="list-style-type: none"> • Dr. Hisataka Kobayashi of the U.S. National Cancer Institute published a paper on photoimmunotherapy, the technology underlying Illuminox™, in the journal, Nature Medicine
2013	<ul style="list-style-type: none"> • Mickey was investor for Aspyrian Therapeutics, Inc. • Additional seed founding from private investors was received • Aspyrian Therapeutics, Inc. granted an exclusive license from the National Institutes of Health to develop and commercialize photoimmunotherapy
2015	<ul style="list-style-type: none"> • Investigational New Drug Application (IND) filed for Phase 1/2a to evaluate RM-1929 in recurrent head and neck squamous cell carcinoma (rHNSCC) in U.S.
2016	<ul style="list-style-type: none"> • Office opened in Sinn-Fleisbach, Germany
2017	<ul style="list-style-type: none"> • Office opened in Tokyo, Japan
2018	<ul style="list-style-type: none"> • Fast Track designation of RM-1929 in rHNSCC by Food and Drug Administration (FDA) • Initiation of Phase 1 trial to evaluate RM-1929 in rHNSCC in Japan • The US corporate headquarters established in San Mateo, California, U.S. • Initiation of Global Phase 3 trial to evaluate ASP-1929** in rHNSCC • Hiroshi Mikitani appointed as CEO
2019	<ul style="list-style-type: none"> • Rebranded company name to Rakuten Medical, Inc. • ASP-1929 in HNC received Sakigake designation by Min. of Health, Labour and Welfare in Japan • Office opened in Taipei, Taiwan and in Amsterdam, Netherlands

Rakuten Medical

2020	<ul style="list-style-type: none">• Submitted a Japanese Biological License Application (JBLA) for ASP-1929 under the Conditional Early Approval System (CEAS) and applied for Japan approval of the laser illumination system• The acquisition of Medlight SA
-------------	---

**RM-1929 and ASP-1929 are analogous. Extensive physiochemical studies show that they have comparable physical and chemical properties.

(As of August 2020)